Alvine Pharmaceuticals, Inc.
Records under this name other than the patents Alvine Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Back to Alvine Pharmaceuticals, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,993,531 | Formulation for oral administration of proteins Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,980,254 | Formulation for oral administration of proteins Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,267,128 | Proteases for degrading gluten Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,434,150 | Methods and pharmaceutical compositions for treating celiac disease and gluten intolerance Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,143,210 | Enzyme Treatment of Foodstuffs for Celiac Sprue Formerly held Lapsed on the fee record Ended Mar 27, 2024 · Medium confidence | Lapsed on the fee record | Ended Mar 27, 2024 | Medium confidence |
| US 7,320,788 | Enzyme Treatment of Foodstuffs for Celiac Sprue Formerly held Term ended Term ended Aug 26, 2023 · High confidence | Term ended | Term ended Aug 26, 2023 | High confidence |
| US 9,017,667 | Dosage forms that facilitate rapid activation of barley protease zymogen Formerly held Lapsed on the fee record Ended Apr 28, 2023 · USPTO record | Lapsed on the fee record | Ended Apr 28, 2023 | USPTO record |
| US 7,628,985 | Therapeutic Enzyme Formulations and Uses Thereof Formerly held Term ended Ended no later than Feb 14, 2023 · Low confidence | Term ended | Ended no later than Feb 14, 2023 | Low confidence |
| US 8,796,201 | Enzyme Treatment of Foodstuffs for Celiac Sprue Formerly held Term ended Term ended Feb 14, 2023 · Medium confidence | Term ended | Term ended Feb 14, 2023 | Medium confidence |
| US 7,563,864 | Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten Formerly held Lapsed on the fee record Ended Jul 21, 2021 · USPTO record | Lapsed on the fee record | Ended Jul 21, 2021 | USPTO record |